This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing Ziopharm’s Sleeping Beauty TCR-T platform targeting neoantigens in solid tumors

Ticker(s): ZIOP

Who's the expert?

An oncologist with clinical practice experience in multiple solid tumors and knowledge about Ziopharm’s Sleeping Beauty TCR-T clinical trials.

Interview Questions

Please tell us about your experience in the TCR-T space. How many patients do you treat with multiple solid tumors, and what percentage of your patients benefit from TCR-T targeting neoantigens?

Added By: slingshot_insights

  1. How much of an unmet need is there for genetic modification of T cells to target cancer? 
  2. Which treatment developments are you most excited about, and can you rate them 1-10? 
  3. Can you compare them to the Sleeping Beauty programme?

Added By: slingshot_insights

What kind of long-term survival results would you like to see in order to be convinced of the drug’s efficacy? What is the best treatment in terms of long-term survival at the moment?

Added By: slingshot_insights

  1. The company demonstrated that T-cell receptors targeting genetic changes within TP53 can be obtained from T cells in the peripheral blood, overcoming the need to harvest a patient’s tumor. How important is this achievement and how would it translate to better patient outcomes? 
  2. What are the risks implicated in obtaining tumor-infiltrating lymphocytes through surgical resection?

Added By: slingshot_insights

What percent of patients’ solid tumors have driver mutations, including TP53?

Added By: slingshot_insights

In a long term outcomes study, four patients demonstrated sustained persistence of CAR-T (median time of persistence duration of 4.5 years, range 2-5 years). Five-year progression-free survival and overall survival were 71% and 86%, respectively. How do you interpret this data point?

Added By: slingshot_insights

How likely would you be to switch your patients to TCR-T Sleeping Beauty therapy in the future?

Added By: slingshot_insights

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.